EcoDrugPlus

5'-Nucleotidase Ecto

Ensembl ID : ENSCVAG00000012478
Gene Symbol: NT5E
3 Cross references
190 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSCVAG00000019773
Gene Symbol: HTR1B
2 Cross references
178 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSCVAG00000019850
Gene Symbol: HTR1B
3 Cross references
180 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSCVAG00000010184
Gene Symbol: HTR1F
3 Cross references
66 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSCVAG00000002069
Gene Symbol: HTR2A
3 Cross references
215 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a-Like

Ensembl ID : ENSCVAG00000003974
Gene Symbol: LOC107097986
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSCVAG00000011519
Gene Symbol: HTR2B
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSCVAG00000007099
Gene Symbol: HTR3A
3 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSCVAG00000007072
Gene Symbol: HTR3B
3 Cross references
175 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSCVAG00000005422
Gene Symbol: HTR4
1 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSCVAG00000002681
Gene Symbol: HTR5A
3 Cross references
215 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSCVAG00000000863
Gene Symbol: HTR6
3 Cross references
115 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).